UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 1, 2012
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 6, 2012, 7,469,483,622 shares of the issuer s voting common stock were outstanding.
FORM 10-Q
For the Quarterly Period Ended
July 1, 2012
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended July 1, 2012 and July 3, 2011
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2012 and July 3, 2011
Condensed Consolidated Balance Sheets as of July 1, 2012 and December 31, 2011
Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2012 and July 3, 2011
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
44
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
45
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
84
Item 4.
Controls and Procedures
84
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
84
Item 1A.
Risk Factors
85
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
86
Item 3.
Defaults Upon Senior Securities
86
Item 4.
Mine Safety Disclosures
86
Item 5.
Other Information
86
Item 6.
Exhibits
86
Signature
87
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
July 1,
2012
July 3,
2011
July 1,
2012
July 3,
2011
Revenues
15,057
16,485
29,942
32,509
Costs and expenses:
Cost of sales(a)
2,752
3,571
5,497
7,040
Selling, informational and administrative expenses(a)
3,977
4,800
7,954
9,178
Research and development expenses(a)
1,699
2,231
3,753
4,311
Amortization of intangible assets
1,291
1,384
2,711
2,749
Restructuring charges and certain acquisition-related costs
190
478
787
1,368
Other deductions net
664
423
2,321
1,255
Income from continuing operations before provision for taxes on income
4,484
3,598
6,919
6,608
Provision for taxes on income
1,290
1,077
2,001
1,951
Income from continuing operations
3,194
2,521
4,918
4,657
Discontinued operations net of tax
66
97
145
195
Net income before allocation to noncontrolling interests
3,260
2,618
5,063
4,852
Less: Net income attributable to noncontrolling interests
16
20
Net income attributable to Pfizer Inc.
3,253
2,610
5,047
4,832
Earnings per common share basic:(b)
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.43
0.32
0.65
0.58
Discontinued operations net of tax
0.01
0.01
0.02
0.02
Net income attributable to Pfizer Inc. common shareholders
0.44
0.33
0.67
0.61
Earnings per common share diluted:(b)
Income from continuing operations attributable to Pfizer Inc.
common shareholders
0.42
0.32
0.65
0.58
Discontinued operations net of tax
0.01
0.01
0.02
0.02
Net income attributable to Pfizer Inc. common shareholders
0.43
0.33
0.67
0.61
Weighted-average shares Basic
7,476
7,875
7,506
7,929
Weighted-average shares Diluted
7,537
7,935
7,570
7,980
Cash dividends paid per common share
0.22
0.20
0.44
0.40
(a)
Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
(b)
EPS amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
July 1,
2012
July 3,
2011
July 1,
2012
July 3,
2011
Net income before allocation to noncontrolling interests
3,260
2,618
5,063
4,852
Other Comprehensive Income/(Loss)
Foreign currency translation adjustments
(1,981
956
(1,718
2,546
Reclassification adjustments(a)
(7
(1,981
956
(1,718
2,539
Unrealized holding gains/(losses) on derivative financial instruments
(657
228
(230
535
Reclassification adjustments for realized (gains)/losses(a)
427
(224
127
(734
(230
(103
(199
Unrealized holding gains/(losses) on available-for-sale securities
12
17
92
(20
Reclassification adjustments for realized (gains)/losses(a)
16
(1
33
28
16
125
(11
Benefit plans: Actuarial gains/(losses)
(505
(504
Reclassification adjustments related to amortization(b)
113
70
230
140
Reclassification adjustments related to curtailments and settlements, net(b)
(8
122
112
173
Other
39
(57
54
(144
(361
138
(108
172
Benefit plans: Prior service credits and other
26
26
Reclassification adjustments related to amortization(b)
(17
(17
(36
(35
Reclassification adjustments related to curtailments and settlements, net(b)
(73
(22
(82
(33
Other
(1
(2
(4
(64
(40
(94
(71
Other comprehensive income/(loss), before tax
(2,608
1,074
(1,898
2,430
Tax benefit on other comprehensive income/(loss)(c)
(205
(32
(1
(60
Other comprehensive income/(loss) before allocation to noncontrolling interests
(2,403
1,106
(1,897
2,490
Comprehensive Income
Comprehensive income before allocation to noncontrolling interests
857
3,724
3,166
7,342
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(10
12
(2
28
Comprehensive income attributable to Pfizer Inc.
867
3,712
3,168
7,314
(a)
Reclassified into Other deductions net in the condensed consolidated statements of income.
(b)
Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate in the condensed consolidated statements of income.
(c)
See Note 5B. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(millions of dollars)
July 1,
2012
Dec. 31,
2011
(Unaudited)
Assets
Cash and cash equivalents
3,031
3,182
Short-term investments
21,275
23,270
Accounts receivable, less allowance for doubtful accounts
12,882
13,058
Inventories
7,001
6,610
Taxes and other current assets
9,215
9,380
Assets of discontinued operations and other assets held for sale
5,361
5,317
Total current assets
58,765
60,817
Long-term investments
10,548
9,814
Property, plant and equipment, less accumulated depreciation
14,756
15,921
Goodwill
44,568
44,569
Identifiable intangible assets, less accumulated amortization
48,399
51,184
Taxes and other noncurrent assets
5,806
5,697
Total assets
182,842
188,002
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
7,703
4,016
Accounts payable
3,165
3,678
Dividends payable
1,826
1,796
Income taxes payable
2,098
1,009
Accrued compensation and related items
1,493
2,120
Other current liabilities
13,215
15,066
Liabilities of discontinued operations
1,298
1,224
Total current liabilities
30,798
28,909
Long-term debt
30,868
34,926
Pension benefit obligations
6,484
6,341
Postretirement benefit obligations
3,309
3,344
Noncurrent deferred tax liabilities
18,487
18,861
Other taxes payable
7,099
6,886
Other noncurrent liabilities
5,836
6,114
Total liabilities
102,881
105,381
Commitments and Contingencies
Preferred stock
42
45
Common stock
447
445
Additional paid-in capital
72,027
71,423
Employee benefit trusts
(2
(3
Treasury stock
(34,863
(31,801
Retained earnings
47,904
46,210
Accumulated other comprehensive loss
(6,008
(4,129
Total Pfizer Inc. shareholders equity
79,547
82,190
Equity attributable to noncontrolling interests
414
431
Total equity
79,961
82,621
Total liabilities and equity
182,842
188,002
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(millions of dollars)
July 1,
2012
July 3,
2011
Operating Activities
Net income before allocation to noncontrolling interests
5,063
4,852
Adjustments to reconcile net income before allocation to noncontrolling interests to net
cash provided by operating activities:
Depreciation and amortization
4,002
4,353
Share-based compensation expense
247
244
Asset write-offs and impairment charges
758
573
Deferred taxes from continuing operations
(120
505
Other deferred taxes
14
(7
Benefit plan contributions in excess of expense
(20
(249
Other non-cash adjustments, net
(114
10
Other changes in assets and liabilities, net of acquisitions and divestitures
(3,035
259
Net cash provided by operating activities
6,795
10,540
Investing Activities
Purchases of property, plant and equipment
(548
(608
Purchases of short-term investments
(10,395
(6,559
Proceeds from redemptions and sales of short-term investments
14,357
4,643
Net proceeds from/(payments for) redemptions and sales of short-term investments with
original maturities of 90 days or less
(999
8,327
Purchases of long-term investments
(2,317
(3,193
Proceeds from redemptions and sales of long-term investments
304
1,572
Acquisitions, net of cash acquired
(782
(3,169
Other investing activities
(56
73
Net cash provided by/(used in) investing activities
(436
1,086
Financing Activities
Proceeds from short-term borrowings
3,764
4,868
Principal payments on short-term borrowings
(2
(2,483
Net payments on short-term borrowings with original maturities of 90 days or less
(4,146
(2,452
Principal payments on long-term debt
(7
(3,481
Purchases of common stock
(2,999
(3,679
Cash dividends paid
(3,283
(3,159
Other financing activities
198
64
Net cash used in financing activities
(6,475
(10,322
Effect of exchange-rate changes on cash and cash equivalents
(35
57
Net increase/(decrease) in cash and cash equivalents
(151
1,361
Cash and cash equivalents, beginning
3,182
1,735
Cash and cash equivalents, end
3,031
3,096
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
1,127
737
Interest
1,194
1,337
See Notes to Condensed Consolidated Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 27, 2012, and May 29, 2011. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to certain inventories (see Note 8. Inventories) and the reclassification of certain investments (see Note 7. Financial Instruments).
We anticipate filing a registration statement with the SEC by mid-August for a potential initial public offering (IPO) of up to a 20% ownership stake in our Animal Health business, Zoetis, Inc. (Zoetis). If the IPO is successfully completed, which we are targeting for the first half of 2013, we will have a variety of options to achieve a potential full separation of Zoetis. The Animal Health business continues to be presented as a continuing operation in these condensed consolidated financial statements.
On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl . As a result, beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, the assets and liabilities associated with this business are reported as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets (see Note 2B. Acquisitions and Divestitures: Divestitures). Prior period amounts have been restated.
On August 1, 2011, we completed the sale of our Capsugel business. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 3, 2011 (see Note 2B. Acquisitions and Divestitures: Divestitures).
As a result of our acquisition of King Pharmaceutical, Inc. (King) and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the six months ended July 3, 2011 reflect approximately five months of King s U.S. operations and approximately four months of King s international operations (for additional information, see Note 2A. Acquisitions and Divestitures: Acquisitions).
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and results of operations.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2011 Annual Report on Form 10-K.
B. Adoption of New Accounting Standards
The provisions of the following new accounting and disclosure standards were adopted as of January 1, 2012:
Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented separate Condensed Consolidated Statements of Comprehensive Income.
An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Note 2. Acquisitions and Divestitures
A. Acquisitions
Alacer Corp.
On February 26, 2012, we completed our acquisition of Alacer Corp., a privately owned company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this consumer healthcare acquisition, we recorded $247 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand, $94 million in net deferred tax liabilities and $151 million in Goodwill. The allocation of the consideration transferred has been finalized.
Ferrosan Holding A/S
On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Due to the fact that financial information included in our fiscal year 2011 consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30, this acquisition is reflected in our condensed consolidated financials beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this acquisition, we recorded $483 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands, $124 million in net deferred tax liabilities and $231 million in Goodwill. The allocation of the consideration transferred has not been finalized.
King Pharmaceuticals, Inc.
On January 31, 2011 (the acquisition date), we completed a tender offer for the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).
King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the assets acquired and liabilities assumed from King:
(millions of dollars)
Amounts
Recognized as of
Acquisition Date
(Final)
Working capital, excluding inventories
155
Inventories
340
Property, plant and equipment
412
Identifiable intangible assets, excluding in-process research and development
1,806
In-process research and development
303
Net tax accounts
(328
All other long-term assets and liabilities, net
102
Total identifiable net assets
2,790
Goodwill(a)
765
Net assets acquired/total consideration transferred
3,555
(a)
Goodwill recorded as of the acquisition date totaled $720 million for our three biopharmaceutical operating segments and $45 million for our Animal Health and Consumer Healthcare operating segment. (Since the acquisition of King, we have revised our operating segments. See Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.)
As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.
Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:
the expected synergies and other benefits that we believed would result from combining the operations of King with the operations of Pfizer;
any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and
the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).
Goodwill is not amortized and is not deductible for tax purposes (see Note 9A. Goodwill and Other Intangible Assets: Goodwill for additional information).
The assets and liabilities arising from contingencies recognized as of the acquisition date are not significant to Pfizer s condensed consolidated financial statements.
The following table provides the actual financial results of King included in the condensed consolidated statement of income:
(millions of dollars)
King s Operations
Included in Pfizer s
Six-Month
2011 Results
Revenues(a)
581
Loss from continuing operations attributable to Pfizer Inc. common shareholders(a), (b)
(74
(a)
From January 31, 2011 (the acquisition date) through Pfizer s second-quarter 2011 domestic and international quarter-ends.
(b)
Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($119 million pre-tax), amortization of identifiable intangible assets acquired from King ($71 million pre-tax) and restructuring and integration costs ($159 million pre-tax).
If the acquisition of King had occurred on January 1, 2011, the change to Pfizer s Revenues, Income from continuing operations attributable to Pfizer Inc. common shareholders and Diluted earnings per share attributable to Pfizer Inc. common shareholders would not have been material.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Divestitures
On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl for $11.85 billion in cash. The transaction is expected to close by the first half of 2013, assuming the receipt of the required regulatory clearances and satisfaction of other closing conditions. Beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. The transaction also includes the sale of certain prenatal multivitamins currently commercialized by the Pfizer Consumer Healthcare business unit. The operating results of this product line are also included in Discontinued operations net of tax for all periods presented. In addition, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets.
On August 1, 2011, we completed the sale of our Capsugel business for approximately $2.4 billion in cash. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 3, 2011.
The following table provides the components of Discontinued operations net of tax:
Three Months Ended
Six Months Ended
(millions of dollars)
July 1,
2012
July 3,
2011
July 1,
2012
July 3,
2011
Revenues(a)
581
714
1,101
1,369
Income from discontinued operations before provision for taxes
on income
119
128
237
263
Provision for taxes on income(b)
(53
(31
(92
(68
Discontinued operations net of tax(a)
66
97
145
195
(a)
Includes the Nutrition business for all periods presented and the Capsugel business for 2011 only.
(b)
Includes deferred tax expense (includes deferred taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries permanent in duration) of $22 million and a deferred tax benefit of $4 million for the three months ended July 1, 2012 and July 3, 2011, respectively, and a deferred tax expense of $14 million and a deferred tax benefit of $7 million for the six months ended July 1, 2012 and July 3, 2011, respectively.
The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations:
(millions of dollars)
July 1,
2012
Dec. 31,
2011
Accounts receivable, less allowance for doubtful accounts
559
550
Inventories
366
359
Prepaid assets
40
45
Current deferred tax assets and other current assets
44
15
Property, plant and equipment, less accumulated depreciation
1,138
1,118
Goodwill
495
498
Identifiable intangible assets, less accumulated amortization
2,620
2,648
Deposits advances and other assets
32
47
Deferred charges
21
23
Noncurrent deferred tax assets and other noncurrent assets
46
14
Assets of discontinued operations and other assets held for sale
5,361
5,317
Current liabilities
427
385
Other liabilities
871
839
Liabilities of discontinued operations
1,298
1,224
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for any period presented.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction and productivity initiatives. For example:
In connection with our cost-reduction and productivity initiatives, significant programs of which began in 2005, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company).
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as information technology, shared services and corporate operations.
Since the acquisition of Wyeth on October 15, 2009, our cost-reduction initiatives announced on January 26, 2009, but not completed as of December 31, 2009, were incorporated into a comprehensive plan to integrate Wyeth s operations to generate cost savings and to capture synergies across the combined company. In addition, on February 1, 2011, we announced a new productivity initiative to accelerate our strategies to improve innovation and productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.
The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: